Ilagan Justin, Sahani Harshini, Saleh Arif Bin, Tavakolian Kameron, Mararenko Anton, Udongwo Ndausung, Douedi Steven, Upadhyaya Vandan, Patel Swapnil, Mushtaq Arman, Sealove Brett, Gonzalez David, Asif Arif
Department of Internal Medicine, Jersey Shore University Medical Center, Neptune City, NJ 07753, USA.
Department of Obstetrics and Gynecology, Monmouth Medical Center, Long Branch, NJ 07740, USA.
J Clin Med Res. 2022 Oct;14(10):395-399. doi: 10.14740/jocmr4792. Epub 2022 Oct 28.
Cardiorenal syndrome (CRS) continues to be an area of concern due to the changing understanding of identification, pathophysiology and optimal management. Originally thought that diuretics were always the answer, recent literature has shed lights on the five major CRS subphenotypes, and while conceptual in their classifications, different strategies may be utilized to manage each type. The effect of CRS in pregnant women is largely under discussed and underappreciated as its own entity. Trials involving possible management, specifically utilizing serelaxin, a recombinant form of relaxin, have shown promising results but more data are needed to begin implementing it on a large scale.
由于对心脏肾综合征(CRS)的识别、病理生理学和最佳管理的认识不断变化,它仍然是一个备受关注的领域。最初认为利尿剂总是解决办法,但最近的文献揭示了CRS的五种主要亚型,虽然其分类是概念性的,但可以采用不同策略来管理每种类型。CRS对孕妇的影响在很大程度上未得到充分讨论和重视,其本身就是一个独立的研究对象。涉及可能的管理方法(特别是使用重组松弛素——希瑞适)的试验已显示出有希望的结果,但还需要更多数据才能开始大规模应用。